MY169147A - Drug-protein conjugates - Google Patents
Drug-protein conjugatesInfo
- Publication number
- MY169147A MY169147A MYPI2015701285A MYPI2015701285A MY169147A MY 169147 A MY169147 A MY 169147A MY PI2015701285 A MYPI2015701285 A MY PI2015701285A MY PI2015701285 A MYPI2015701285 A MY PI2015701285A MY 169147 A MY169147 A MY 169147A
- Authority
- MY
- Malaysia
- Prior art keywords
- drug
- conjugates
- protein conjugates
- specific
- peptide
- Prior art date
Links
- 239000000562 conjugate Substances 0.000 abstract 3
- 102000014914 Carrier Proteins Human genes 0.000 abstract 2
- 108091008324 binding proteins Proteins 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000000611 antibody drug conjugate Substances 0.000 abstract 1
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717743P | 2012-10-24 | 2012-10-24 | |
| US201261717710P | 2012-10-24 | 2012-10-24 | |
| US201361811285P | 2013-04-12 | 2013-04-12 | |
| PCT/GB2013/051593 WO2013190292A2 (en) | 2012-06-19 | 2013-06-19 | Novel process for preparation of antibody conjugates and novel antibody conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY169147A true MY169147A (en) | 2019-02-18 |
Family
ID=50544085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2015701285A MY169147A (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20150290342A1 (enExample) |
| EP (2) | EP3159013A1 (enExample) |
| JP (1) | JP6328648B2 (enExample) |
| KR (1) | KR102209395B1 (enExample) |
| CN (1) | CN104870021B (enExample) |
| AU (1) | AU2013336409B2 (enExample) |
| BR (1) | BR112015008376A2 (enExample) |
| CA (1) | CA2884299A1 (enExample) |
| DK (1) | DK2911700T5 (enExample) |
| ES (1) | ES2623209T3 (enExample) |
| IL (1) | IL237672B (enExample) |
| IN (1) | IN2015DN02349A (enExample) |
| MX (1) | MX2015005122A (enExample) |
| MY (1) | MY169147A (enExample) |
| RU (1) | RU2015119561A (enExample) |
| SG (1) | SG11201501618WA (enExample) |
| WO (1) | WO2014064423A1 (enExample) |
| ZA (1) | ZA201501642B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160018579A (ko) * | 2013-06-04 | 2016-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항체를 접합하기 위한 조성물 및 방법 |
| JP6747971B2 (ja) | 2013-10-15 | 2020-08-26 | シアトル ジェネティックス， インコーポレイテッド | 改善されたリガンド−薬物コンジュゲート薬物動態のためのｐｅｇ化薬物−リンカー |
| EP3145552B1 (en) * | 2014-05-23 | 2020-03-04 | Novartis AG | Methods for making conjugates from disulfide-containing proteins |
| MY177148A (en) * | 2014-06-12 | 2020-09-08 | Cspc Megalith Biopharmaceutical Co Ltd | Homogenous antibody drug conjugates via enzymatic methods |
| ES2885854T3 (es) | 2014-10-14 | 2021-12-15 | Polytherics Ltd | Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG |
| US20170290925A1 (en) * | 2014-10-24 | 2017-10-12 | Polytherics Limited | Conjugates And Conjugating Reagents |
| GB201419108D0 (en) | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
| CN107043406B (zh) | 2015-11-03 | 2021-08-17 | 财团法人工业技术研究院 | 化合物、连接子-药物、及配体-药物耦合体 |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| EP3433278A4 (en) | 2016-03-25 | 2019-11-06 | Seattle Genetics, Inc. | METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF |
| WO2017178828A1 (en) | 2016-04-14 | 2017-10-19 | Polytherics Limited | Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring |
| GB201608936D0 (en) | 2016-05-20 | 2016-07-06 | Polytherics Ltd | Novel conjugates and novel conjugating reagents |
| ES2965349T3 (es) * | 2016-06-06 | 2024-04-12 | Abzena Uk Ltd | Anticuerpos, usos de los mismos y conjugados de los mismos |
| GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| CN110430901B (zh) | 2017-03-24 | 2024-08-16 | 西雅图基因公司 | 制备葡糖苷酸药物-接头及其中间体的方法 |
| GB201820864D0 (en) * | 2018-12-20 | 2019-02-06 | J A Kemp | Antibody-drug conjugates |
| CN119345387A (zh) * | 2020-04-15 | 2025-01-24 | 深圳康源久远生物技术有限公司 | 抗体药物缀合物 |
| US20240181074A1 (en) * | 2021-03-19 | 2024-06-06 | Shenzhen Enduring Biotech, Ltd. | Pegylated t cell engager with dual specificities to cd3 and cd19 |
| US20250222124A1 (en) * | 2022-01-27 | 2025-07-10 | Glyco-Therapy Biotechnology Co., Ltd. | Protein conjugates with multiple payloads and methods for making the same |
| TW202444426A (zh) * | 2023-03-29 | 2024-11-16 | 美商艾克塞里克斯公司 | Amhrii抗體-藥物結合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| ES2456325T3 (es) | 2003-11-06 | 2014-04-22 | Seattle Genetics, Inc. | Compuestos de monometilvalina capaces de conjugación con ligandos |
| EP2354163A3 (en) * | 2005-09-26 | 2013-04-24 | Medarex, Inc. | Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies |
| US7968687B2 (en) * | 2007-10-19 | 2011-06-28 | Seattle Genetics, Inc. | CD19 binding agents and uses thereof |
| US8609105B2 (en) | 2008-03-18 | 2013-12-17 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| MX2010011808A (es) * | 2008-04-30 | 2011-03-04 | Immunogen Inc | Conjugados potentes y enlazadores hidrofilicos. |
| WO2010100430A1 (en) | 2009-03-04 | 2010-09-10 | Polytherics Limited | Conjugated proteins and peptides |
| MX2011010264A (es) * | 2009-04-01 | 2011-10-11 | Genentech Inc | Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso. |
| UY32913A (es) * | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero |
| JP6384963B2 (ja) * | 2012-04-25 | 2018-09-05 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 勾配コイルを置くためのシステム及び方法 |
| EP2861261A2 (en) * | 2012-06-19 | 2015-04-22 | Polytherics Limited | Process for preparation of antibody conjugates and antibody conjugates |
-
2013
- 2013-10-11 IN IN2349DEN2015 patent/IN2015DN02349A/en unknown
- 2013-10-11 EP EP16203350.0A patent/EP3159013A1/en not_active Withdrawn
- 2013-10-11 RU RU2015119561A patent/RU2015119561A/ru unknown
- 2013-10-11 KR KR1020157011427A patent/KR102209395B1/ko active Active
- 2013-10-11 MX MX2015005122A patent/MX2015005122A/es unknown
- 2013-10-11 MY MYPI2015701285A patent/MY169147A/en unknown
- 2013-10-11 AU AU2013336409A patent/AU2013336409B2/en active Active
- 2013-10-11 SG SG11201501618WA patent/SG11201501618WA/en unknown
- 2013-10-11 BR BR112015008376A patent/BR112015008376A2/pt not_active Application Discontinuation
- 2013-10-11 CN CN201380055880.6A patent/CN104870021B/zh active Active
- 2013-10-11 JP JP2015538560A patent/JP6328648B2/ja active Active
- 2013-10-11 ES ES13786530.9T patent/ES2623209T3/es active Active
- 2013-10-11 WO PCT/GB2013/052661 patent/WO2014064423A1/en not_active Ceased
- 2013-10-11 EP EP13786530.9A patent/EP2911700B1/en active Active
- 2013-10-11 CA CA2884299A patent/CA2884299A1/en not_active Abandoned
- 2013-10-11 US US14/437,537 patent/US20150290342A1/en not_active Abandoned
- 2013-10-11 DK DK13786530.9T patent/DK2911700T5/en active
-
2015
- 2015-03-10 ZA ZA2015/01642A patent/ZA201501642B/en unknown
- 2015-03-11 IL IL237672A patent/IL237672B/en active IP Right Grant
-
2021
- 2021-09-17 US US17/477,565 patent/US20220062436A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2884299A1 (en) | 2014-05-01 |
| US20220062436A1 (en) | 2022-03-03 |
| CN104870021B (zh) | 2018-03-13 |
| AU2013336409A1 (en) | 2015-04-02 |
| SG11201501618WA (en) | 2015-04-29 |
| DK2911700T3 (en) | 2017-05-15 |
| US20150290342A1 (en) | 2015-10-15 |
| EP2911700B1 (en) | 2017-02-08 |
| JP6328648B2 (ja) | 2018-05-23 |
| CN104870021A (zh) | 2015-08-26 |
| KR102209395B1 (ko) | 2021-01-28 |
| KR20150103656A (ko) | 2015-09-11 |
| DK2911700T5 (en) | 2017-05-22 |
| BR112015008376A2 (pt) | 2017-09-26 |
| EP3159013A1 (en) | 2017-04-26 |
| EP2911700A1 (en) | 2015-09-02 |
| JP2015533847A (ja) | 2015-11-26 |
| RU2015119561A (ru) | 2016-12-20 |
| WO2014064423A1 (en) | 2014-05-01 |
| AU2013336409B2 (en) | 2017-08-03 |
| IL237672A0 (en) | 2015-04-30 |
| MX2015005122A (es) | 2015-10-29 |
| IL237672B (en) | 2018-02-28 |
| IN2015DN02349A (enExample) | 2015-08-28 |
| ZA201501642B (en) | 2016-01-27 |
| ES2623209T3 (es) | 2017-07-10 |
| HK1208187A1 (en) | 2016-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY169147A (en) | Drug-protein conjugates | |
| MX2015005124A (es) | Conjugados de farmaco-proteina. | |
| PH12014501039B1 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| CY1123739T1 (el) | Αντισωματα anti-cd38 | |
| MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
| NZ703581A (en) | Anti-cd70 antibody drug conjugates | |
| MX347893B (es) | Conjugados de farmaco y anticuerpo humano contra factor de tejido. | |
| MX2016007865A (es) | Peptidos citotoxicos y conjugados de los mismos. | |
| PH12019501330A1 (en) | Antibody drug conjugates for ablating hematopoietic stem cells | |
| PH12013501942A1 (en) | Antibody-drug conjugates | |
| PH12016501171A1 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
| MX353608B (es) | Anticuerpo modificado en el que el tema que comprende residuos de cisteina esta ligado, conjugado de farmaco de anticuerpo modificado que comprende el anticuerpo modificado y metodo de produccion para el mismo. | |
| PH12016501995A1 (en) | Tubulysin derivatives | |
| TN2015000396A1 (en) | Antibody drug conjugates | |
| TN2014000148A1 (en) | Antigen binding protein and its use as addressing product for the treatment of cancer | |
| MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
| MY181648A (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
| NZ630542A (en) | Methods of treating a tauopathy | |
| MX2015002371A (es) | Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos. | |
| MY208842A (en) | Drug conjugates of cmet monoclonal binding agents, and uses thereof | |
| PH12013500432A1 (en) | Anti-vegfr-3 antibody compositions | |
| MX2013003168A (es) | Anticuerpo contra ephrin b2 y su uso. | |
| WO2016055568A3 (en) | Prr11 binding agents for cancer therapy | |
| TN2011000153A1 (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide |